Fuda Cancer Hospital Cryoablation: Evidence, Risks & Case Fit
Cryoablation destroys a local tumor by repeated freezing and thawing, usually with image-guided probes placed through the skin. FUDA has used cryosurgery for many years and still lists Cryosurgical Ablation (CSA) in its treatment directory, with current 2026 activity in lung, liver, kidney and adrenal tumor ablation.
Quick answer: cryoablation is a legitimate local-ablation technique, but its evidence is
organ- and stage-specific. The strongest modern evidence is not “cryo works for almost every solid tumor.”
It is that selected patients with small lung tumors, selected renal tumors and some other local lesions may benefit from
image-guided cryoablation when surgery, radiation or another ablation strategy is not preferred. FUDA’s broad historical
claims should therefore be narrowed to the patient’s exact disease.
✓ Local treatment ≠ whole-body cancer treatment
✓ Lung / kidney evidence separated from pancreatic evidence
✓ FUDA marketing claims independently framed
✓ No universal success-rate claim
What Is Cryoablation?
Freeze–thaw destruction of a local target
Percutaneous cryoablation places one or more cryoprobes into a tumor under CT or ultrasound guidance. Repeated freeze–thaw cycles form an “ice ball” that can be monitored during treatment and is intended to destroy tumor tissue.
Image-visible ablation zone
A practical feature of cryoablation is that the ice ball is visible on imaging. This can help the operator monitor the treatment margin and its relationship to nearby organs during the procedure.
Do not turn an old device claim into a cancer approval claim. FUDA’s cryosurgery page dates to 2014
and contains broad historical FDA / regulatory and efficacy language. ParkMega uses it to document what FUDA says it offers,
not as proof that cryoablation is FDA-approved or guideline-preferred for every listed cancer.
Is FUDA Still Actively Performing Cryoablation in 2026?
Yes — current FUDA material shows an active cryoablation program. In April 2026 the hospital reported
visiting experts observing cryoablation procedures involving liver, lung, kidney and adrenal tumors.
In May 2026, FUDA reported Niu Lizhi giving presentations on lung cryoablation and broader clinical applications,
and WATA 2026 included a FUDA presentation on liver cryoablation technique.
Lung cryoablation expert exchange
FUDA reported observation of cryo procedures in lung, liver, kidney and adrenal tumors during a Guangdong–Hong Kong exchange.
ESTIR: lung cryoablation
FUDA reported Niu Lizhi presenting on “Cryoablation for Lung Cancer” and clinical advances in cryoablation.
WATA: liver cryoablation
FUDA reported a presentation on standardization and techniques of cryoablation for liver cancer at WATA 2026.
These 2026 items confirm program activity and academic engagement. They do not establish comparative survival benefit.
Which Cases May Be Reasonable to Review for Cryoablation?
Small primary or metastatic lung tumors
Modern image-guided lung-ablation literature supports cryoablation as a local option in selected patients, particularly when surgery is not ideal and the disease burden is limited. Tumor size strongly affects local control.
Selected cT1 renal tumors
A 2024 systematic review found percutaneous cryoablation had fewer complications than partial nephrectomy and similar local recurrence-free survival in cT1a tumors, but worse local control in cT1b disease.
Historical FUDA experience ≠ modern standard
FUDA published pancreatic cryoablation cohorts more than a decade ago. These show historical technical experience, but they should not be used to imply that pancreatic cryoablation is a current standard substitute for modern systemic, surgical or radiation-based pancreatic-cancer care.
Organ-specific evidence must be checked
FUDA’s older page lists many solid tumors, but a broad hospital list is not a treatment indication. Liver, adrenal, bone, soft-tissue and other tumors require disease-specific evidence and multidisciplinary comparison.
Lung Cryoablation Evidence in 2026
19 studies · 786 patients · 1,048 lung tumors
A 2026 JVIR systematic review and meta-analysis reported pooled one-year local tumor control of 90.5% after percutaneous cryoablation. Smaller tumors were associated with better local control. Grade ≥3 adverse events were pooled at 4.9%; pneumothorax was the most common adverse event overall.
Local control is not the same as survival superiority
The included studies varied in tumor type, protocol and patient selection. A high local-control estimate does not prove that cryoablation is better than surgery, SBRT, microwave ablation or radiofrequency ablation for every patient.
A separate 2026 meta-analysis of early-stage lung cancer included only seven single-arm pilot studies with 353 patients.
It described cryoablation as a feasible minimally invasive option with acceptable short- to mid-term outcomes, especially
in stage IA disease. The single-arm design means comparative certainty remains limited.
FUDA’s Lung Cryoablation Research
| Publication | What it studied | Design | What it proves |
|---|---|---|---|
| PMID 30964113 | CT-guided percutaneous cryoablation for lung ground-glass opacity | 2019 pilot study | Documents FUDA-linked early experience; not a randomized comparison. |
| PMID 35490929 | CT-guided cryoablation for GGO-dominant lung nodules | 2022 retrospective study · 50 patients | Provides a larger FUDA-affiliated lung-GGO series; selection and retrospective design limit causal claims. |
| 2024 AATS consensus citation | FUDA’s 2019 GGO paper was cited in the AATS expert consensus on subsolid pulmonary nodules | Independent consensus referenced the study | Shows the study entered the literature base; it does not mean AATS endorsed FUDA or cryoablation for all GGOs. |
Renal Tumors: Where Cryoablation Has Stronger Comparative Evidence
A 2024 systematic review and meta-analysis of 6,487 patients compared percutaneous cryoablation with
partial nephrectomy for cT1 renal tumors. Cryoablation had lower overall and major postoperative complication rates.
For cT1a tumors, local recurrence-free survival was not reduced versus partial nephrectomy; for
cT1b, cryoablation had a meaningful local-control disadvantage.
This is why a FUDA renal cryo proposal should include tumor size, nephrometry / complexity, location, kidney function, contralateral kidney status and why surgery is not preferred. “Kidney cancer can be frozen” is not enough.
Pancreatic Cryoablation at FUDA: Historical Evidence, Not a Modern Shortcut
32-patient pancreatic cryo series
A 2012 FUDA retrospective study evaluated 49 cryoablation procedures in 32 pancreatic-cancer patients and reported feasibility, pain improvement and local imaging response. The cohort included stage II–IV disease and predates today’s systemic-treatment landscape.
106 metastatic pancreatic-cancer patients
A 2013 retrospective FUDA study compared cryoimmunotherapy, cryotherapy, immunotherapy and chemotherapy groups. Its survival findings are hypothesis-generating historical data and should not be projected onto current pancreatic cancer care without modern comparative validation.
Cryosurgery + iodine-125 seeds
FUDA authors reported a 49-patient locally advanced pancreatic-cancer series combining cryosurgery with iodine-125 brachytherapy. This is another historical institutional cohort, not evidence that the combination is standard care today.
Compare with modern pancreas standards first
Any 2026 pancreatic cryo proposal should be compared against resectability, systemic regimen, molecular profile, radiation options, disease distribution and a pancreas-specialist multidisciplinary opinion.
What Are the Main Cryoablation Risks?
Pneumothorax and bleeding
Pneumothorax is common after percutaneous lung cryoablation; some patients require chest-tube drainage. Pulmonary bleeding, pain, infection and injury to adjacent structures are additional concerns.
Bleeding and collateral-organ injury
Renal or abdominal procedures can cause hemorrhage, urinary-tract injury, bowel or nerve injury and damage to adjacent structures. Hydrodissection or other protective techniques may be required.
Incomplete margin or recurrence
Tumor size, difficult geometry, proximity to heat-producing blood flow and inability to create an adequate ice-ball margin can reduce local-control probability and may require repeat treatment.
Ablation can control one target while cancer progresses elsewhere
Cryoablation treats the targeted lesion. It should not be described as systemic treatment simply because immune changes have been observed or hypothesized after freezing.
Does Cryoablation “Activate the Immune System”?
This is one of the easiest FUDA claims to overstate. FUDA frequently discusses “cryo-immunity” and
combinations with PD-1 therapy. Biological immune effects after tumor freezing are scientifically plausible and actively
studied, but they do not justify telling a patient that cryoablation will create a systemic anti-cancer immune response
or replace immunotherapy.
FUDA reported Liu Shupeng presenting a cryoablation + PD-1 inhibitor + chemotherapy strategy for advanced lung cancer at SIO 2026. That is evidence of current research / academic activity. Treatment-effect claims require peer-reviewed, disease-specific comparative evidence before being presented as established benefit.
Cryoablation vs Surgery, SBRT, Microwave, RFA and NanoKnife
| Option | Main role | Potential advantage | What must be compared |
|---|---|---|---|
| Surgery | Resection when disease and patient are operable | Removes tumor and provides full pathology | Operability, disease-specific survival evidence, functional cost |
| Cryoablation | Selected image-guided local ablation | Visible ice ball; repeatable; useful in selected nonsurgical cases | Tumor size/location, organ evidence, margin, complications |
| SBRT | Noninvasive high-dose focused radiation | No probe placement | Prior radiation, lesion location, radiation tolerance and comparative evidence |
| Microwave / RFA | Thermal ablation | Established in several organ-specific settings | Heat-sink, lesion size, location, operator experience |
| NanoKnife / IRE | Non-thermal electrical ablation | May be considered near selected critical structures | Much more indication-specific; evidence and device protocol matter |
Which FUDA Doctors Are Linked to Cryoablation?
Prof. Niu Lizhi
FUDA’s current material repeatedly links Niu Lizhi with cryoablation, including 2026 lung and liver presentations and live procedure / expert-exchange reports. Actual appointment and procedure responsibility still require confirmation.
Dr. Liu Shupeng
FUDA’s profile lists cryosurgical ablation among Liu Shupeng’s techniques. He is also first author of FUDA-affiliated lung cryoablation studies and presented a combined cryo / PD-1 / chemotherapy strategy at SIO 2026.
See the full Fuda Cancer Hospital Doctors guide for the doctor / specialty map.
What Records Are Needed for a FUDA Cryoablation Review?
Core oncology file
- Pathology report and exact cancer type
- Current stage and all known metastatic sites
- Recent contrast CT / MRI
- PET-CT when relevant
- DICOM imaging files when available
- Previous surgery, radiation and systemic treatment
- Relevant molecular / biomarker results
Cryo-specific questions
- Number, dimensions and locations of lesions
- Relationship to vessels, bowel, pleura, bronchi, kidney collecting system or nerves
- Why surgery or SBRT is not preferred
- Whether all active disease can be locally addressed
- What systemic therapy continues before / after ablation
- What margin and protective techniques are planned
Questions to Ask FUDA Before Accepting Cryoablation
What exact lesion are you treating?
Ask for organ, size, location, number of lesions and whether the target is primary cancer, metastasis or a lung nodule still requiring diagnosis.
Why cryo rather than surgery, SBRT, microwave or RFA?
The answer should be anatomy- and evidence-based, not simply “less invasive.”
What is the treatment goal?
Clarify whether the aim is definitive local control, oligometastatic control, palliation, symptom relief or cytoreduction.
Who will perform it and under what image guidance?
Confirm operator, department, CT / ultrasound guidance, anesthesia and protection of adjacent organs.
What complications are most likely for my anatomy?
Ask for organ-specific risks, expected chest tube / ICU / hospital-stay requirements and what would trigger conversion or additional intervention.
What is included in the written estimate?
Confirm probes, imaging, anesthesia, procedure, pathology/biopsy, medicines, room, ICU if needed, follow-up imaging and likely exclusions.
How Much Does FUDA Cryoablation Cost?
A reliable cryoablation price depends on the organ, tumor number and size, number of probes, imaging guidance,
anesthesia, protective maneuvers, hospital stay and whether biopsy, embolization, brachytherapy or systemic treatment
is performed around the procedure.
Use the dedicated Fuda Cancer Hospital Cost guide to evaluate a written estimate rather than comparing a single procedure price.
How ParkMega Reviews a FUDA Cryoablation Proposal
Start with the tumor map, not the freezing technology
Send pathology, stage, imaging and prior treatment. We can separate the strong organ-specific evidence from older FUDA experience, identify the right doctor / department questions, and compare surgery, SBRT or another ablation route when needed.
Related FUDA and China Cancer Guides
Frequently Asked Questions
Direct answers about FUDA cryoablation evidence, eligibility, risks, doctors, lung/kidney use and cost.
What is cryoablation at Fuda Cancer Hospital?
Cryoablation, also called cryosurgical ablation or cryosurgery, is a local treatment in which probes freeze and thaw a tumor under imaging guidance. FUDA continues to list Cryosurgical Ablation in its therapies directory and reported active lung, liver, kidney and adrenal cryo procedures in 2026.
Does FUDA currently perform cryoablation?
Yes. FUDA’s 2026 news reports current cryoablation procedures and academic activity, including a Guangdong–Hong Kong lung-cryo exchange and presentations on lung and liver cryoablation. Current doctor availability and case acceptance should still be confirmed directly.
Which cancers can be treated with cryoablation?
There is no single all-cancer indication. Evidence is strongest in selected organ-specific settings such as small lung tumors and selected renal tumors, while evidence in pancreas and many other cancers is more limited or historical. The diagnosis, stage, tumor size, anatomy and treatment goal must be reviewed separately.
How effective is cryoablation for lung tumors?
A 2026 systematic review and meta-analysis of 19 studies, 786 patients and 1,048 lung tumors reported pooled one-year local tumor control of 90.5%. Smaller tumors had better local control. This result describes local control in selected patients and does not prove superiority to surgery, SBRT or other ablation techniques.
What are the risks of lung cryoablation?
Pneumothorax is the most common complication after percutaneous lung cryoablation, and some patients require chest-tube drainage. Bleeding, pain, infection and injury to adjacent structures can also occur. Risk depends strongly on tumor location, lung reserve and the planned probe path.
Can cryoablation be used for kidney cancer?
Yes in selected renal tumors. A 2024 meta-analysis comparing percutaneous cryoablation with partial nephrectomy found fewer complications with cryoablation and similar local recurrence-free survival in cT1a tumors, but worse local control for cT1b disease. Surgery remains an important comparator.
Does FUDA use cryoablation for pancreatic cancer?
FUDA published pancreatic cryoablation cohorts more than a decade ago, including studies from 2012 and 2013. These papers document historical institutional experience but should not be treated as proof that pancreatic cryoablation is a modern standard or a substitute for current multidisciplinary pancreatic-cancer care.
Does cryoablation activate the immune system?
Tumor freezing can produce immune changes and cryo-immunology is an active research area. FUDA also reports combined cryoablation and immunotherapy strategies. However, this does not mean cryoablation reliably creates a systemic anti-cancer immune response or replaces established immunotherapy.
Which FUDA doctors are associated with cryoablation?
FUDA’s current material repeatedly links Niu Lizhi with cryoablation, while Liu Shupeng’s profile lists cryosurgical ablation and his PubMed record includes lung cryoablation research. A website profile does not guarantee that a named doctor will personally review or perform an international patient’s procedure.
Is cryoablation better than NanoKnife / IRE?
Neither technique is universally better. Cryoablation freezes tissue and allows direct imaging of the ice ball. IRE uses electrical pulses and is non-thermal. Tumor type, size, anatomy, nearby vessels or ducts, evidence level and operator experience determine which local technique, if any, is appropriate.
What records should I send for a FUDA cryoablation review?
Send pathology, stage, recent contrast CT or MRI, DICOM imaging when available, metastatic sites, previous surgery/radiation/systemic therapy, relevant biomarkers and the precise lesion being considered for ablation. For lung or renal lesions, include the most recent thin-slice imaging.
How much does FUDA cryoablation cost?
A case-specific written estimate is more useful than a generic price. Cost can depend on the organ, number and size of tumors, number of cryoprobes, imaging guidance, anesthesia, protective techniques, hospital stay and any additional biopsy, embolization, brachytherapy or systemic treatment.
Sources and Evidence
- FUDA — Cryosurgical Ablation (CSA). Hospital-published description of cryoablation technique and broad claimed applications; page dated 2014, so broad claims are not treated as current independent guidance. Official FUDA cryo page.
- FUDA — Guangdong–Hong Kong Lung Cryoablation Exchange, May 2026. Current hospital-reported procedures involving liver, lung, kidney and adrenal tumors. FUDA report.
- FUDA — ESTIR, May 2026. Hospital-reported presentations on lung cryoablation and clinical applications. FUDA report.
- FUDA — WATA 2026. Hospital-reported presentation on standardization and techniques of liver cryoablation. FUDA report.
- FUDA — SIO 2026. Hospital-reported presentation by Liu Shupeng on cryoablation combined with PD-1 inhibition and chemotherapy for advanced lung cancer; treated here as research/activity signal. FUDA report.
- Sarshoghi et al., 2026 — PMID 41076068. Systematic review/meta-analysis of percutaneous cryoablation for primary and metastatic lung tumors: 19 studies, 786 patients, 1,048 tumors. PubMed.
- Early-stage lung cancer meta-analysis, 2026 — PMID 42306754. Seven single-arm pilot studies / 353 patients; useful but limited by non-comparative design. PubMed.
- Liu et al., 2022 — PMID 35490929. FUDA-affiliated retrospective study of CT-guided cryoablation for GGO-dominant lung nodules. PubMed.
- Liu et al., 2019 — PMID 30964113. FUDA-affiliated pilot study of CT-guided cryoablation for lung ground-glass opacity. PubMed.
- Nowak et al., 2024 — PMID 38539509. Systematic review/meta-analysis comparing percutaneous cryoablation and partial nephrectomy for cT1 renal tumors. PubMed.
- Niu et al., 2012 — PMID 22960266. Historical FUDA pancreatic cryoablation feasibility/safety cohort. PubMed.
- Niu et al., 2013 — PMID 23899940. Historical retrospective FUDA study of cryoablation / cryoimmunotherapy in metastatic pancreatic cancer. PubMed.
- Xu et al., 2013 — PMID 25083464. Historical FUDA-associated series combining pancreatic cryosurgery and iodine-125 brachytherapy. PubMed.
Evidence rule: FUDA sources establish what the hospital says it offers and what activity it reports. Independent reviews and peer-reviewed studies are used to judge how strong the evidence is for each organ and indication.
Medical note: This page does not diagnose cancer or recommend cryoablation for a specific patient. Treatment selection should be based on disease-specific multidisciplinary review.
Check the Lesion and Evidence Before Choosing Cryoablation
Send pathology, stage, recent imaging and prior treatment. We can structure the FUDA questions around tumor size, anatomy, treatment goal, alternatives, operator / department and a written estimate.
✓ Organ-specific evidence
✓ No “works for all solid tumors” claim
✓ Historical pancreas data labeled historical
✓ Alternatives compared before travel
Check whether Fuda cryoablation fits your case
Start with pathology, stage and imaging. The goal is to test organ-specific evidence, tumor anatomy, alternatives, risks and what must be confirmed with Fuda before travel.